{"id":"NCT03961529","sponsor":"Otsuka Pharmaceutical Co., Ltd.","briefTitle":"Long-term Trial of OPA-15406 Ointment in Adult and Pediatric Patients With Atopic Dermatitis","officialTitle":"A Multicenter, Open-label, Uncontrolled, Long-term Trialto Demonstrate the Safety and Efficacy of 1% OPA-15406 Ointment in Adult Patients With Atopic Dermatitis and of 0.3% and 1% OPA-15406 Ointments in Pediatric Patients With Atopic Dermatitis (Phase 3 Trial)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-05-14","primaryCompletion":"2020-11-11","completion":"2020-11-11","firstPosted":"2019-05-23","resultsPosted":"2021-11-19","lastUpdate":"2021-11-19"},"enrollment":366,"design":{"allocation":"NON_RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Atopic Dermatitis"],"interventions":[{"type":"DRUG","name":"0.3% OPA-15406 ointment","otherNames":[]},{"type":"DRUG","name":"1% OPA-15406 ointment","otherNames":[]}],"arms":[{"label":"0.3% OPA-15406 ointment","type":"EXPERIMENTAL"},{"label":"1% OPA-15406 ointment","type":"EXPERIMENTAL"}],"summary":"To demonstrate the safety of 1% OPA-15406 ointment in adult patients with AD and of 0.3% and 1% OPA-15406 ointments in pediatric patients with AD administered twice daily for 52 weeks.","primaryOutcome":{"measure":"Number of Subjects Experiencing Treatment-Emergent Adverse Events (TEAEs)","timeFrame":"Treatment period (52 weeks)","effectByArm":[{"arm":"Adult: 1% OPA-15406 Ointment","deltaMin":120,"sd":null},{"arm":"Pediatric: 0.3% OPA-15406 Ointment","deltaMin":131,"sd":null},{"arm":"Pediatric: 1% OPA-15406 Ointment","deltaMin":47,"sd":null}],"pValues":[]},"eligibility":{"minAge":"2 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":null},"locations":{"siteCount":1,"countries":["Japan"]},"refs":{"pmids":["35716332"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":166},"commonTop":["Nasopharyngitis","Dermatitis atopic","Impetigo","Influenza","Conjunctivitis allergic"]}}